Signal Peptide Peptidase-Like 2b affects APP cleavage and exhibits a biphasic Aβ-mediated expression in Alzheimer's disease.
Maccioni, R.; Travisan, C.; Zerial, S.; Wagener, A.; Andrade-Talavera, Y.; Picciau, F.; Grassi, C.; Chen, G.; Lemoine, L.; Fisahn, A.; Jiang, R.; Fluhrer, R.; Mentrup, T.; Schröder, B.; Nilsson, P.; Tambaro, S.
Show abstract
Alzheimers disease (AD) is a multifactorial disorder driven by abnormal amyloid {beta}-peptide (A{beta}) levels. To identify new druggable pathways involved in the A{beta} cascade we here investigated the AD pathophysiological role of the presenilin-like intramembrane protease signal peptide peptidase-like 2b (SPPL2b). A{beta}42 induced a biphasic modulation of SPPL2b expression in human cell lines and ex vivo mouse brain slices. In addition, SPPL2b was elevated in AppNL-G-F knock-in AD mice as well as in human AD samples. Early high neuronal expression of SPPL2b was followed by a downregulation in late AD pathology in both AppNL-G-F mice and Braak stage V AD brains. Importantly, SPPL2b overexpression or its genetic deletion significantly increased or reduced APP cleavage and A{beta} production, respectively. Thus, our results strongly support the involvement of SPPL2b in AD pathology. The early A{beta}-induced SPPL2b upregulation may enhance A{beta} production in a vicious cycle further aggravating the A{beta} pathology suggesting SPPL2b as a potential anti-A{beta} drug target.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- C5aR1 antagonism alters microglial polarization and mitigates disease progression in a mouse model of Alzheimers disease 98%
- Protein farnesylation is upregulated in Alzheimer's human brains and neuron-specific suppression of farnesyltransferase mitigates pathogenic processes in Alzheimer's model mice 98%
- Aβ oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer's disease. 97%
Similar papers in this journal
- Diabetic phenotype in mouse and humans with β-amyloid pathology reduces the number of microglia around β-amyloid plaques 97%
- Amyloid plaque deposition accelerates tau propagation via activation of microglia in a humanized APP mouse model 96%
- TREM2-H157Y Increases Soluble TREM2 Production and Reduces Amyloid Pathology 95%
Similar papers in this journal
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.